Related Experiment Video
Updated: Jun 18, 2025
Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
Published on: August 9, 2024
[Ocular surface adverse reactions of antitumor-targeted drugs]
1Department of Ophthalmology, Peking University Third Hospital, Beijing Key Laboratory of Restoration of Damaged Ocular Nerve, Beijing 100191, China.
Abstract:
With the extensive application of targeted drugs, the survival rate of cancer patients has been significantly improved. However, adverse reactions to the drugs have also become apparent, especially those affecting the ocular surface, which can severely impact patients' vision and quality of life. The article systematically analyzes a variety of targeted drugs, including epidermal growth factor receptor inhibitors, human epidermal growth factor receptor 2 inhibitors, fibroblast growth factor receptor inhibitors, selective estrogen receptor modulators, vascular endothelial growth factor receptor inhibitors, aromatase inhibitors, proteasome inhibitors, antibody-drug conjugates, Bruton's tyrosine kinase inhibitors, FMS-like tyrosine kinase 3 inhibitors, and cyclin-dependent kinase inhibitors, and discusses their adverse reactions on the ocular surface. The review emphasizes the role of clinicians in monitoring and managing patients' ocular surface health and the importance of early diagnosis and intervention to ensure that patients receive optimal visual protection while undergoing antitumor treatment.
Insights
Targeted cancer therapies improve survival but can cause ocular surface adverse reactions. Early monitoring and intervention are crucial for preserving vision during cancer treatment.
Area of Science:
- Oncology
- Ophthalmology
- Pharmacology
Background:
- Targeted cancer therapies have improved patient survival rates.
- Adverse drug reactions, particularly on the ocular surface, are a growing concern.
- Ocular surface toxicity can significantly impair vision and quality of life.
Purpose of the Study:
- To systematically review ocular surface adverse reactions associated with various targeted cancer drugs.
- To highlight the importance of clinical monitoring and management of ocular health in cancer patients.
- To emphasize early diagnosis and intervention for visual protection during cancer therapy.
Main Methods:
- Systematic analysis of targeted drug classes.
- Review of documented ocular surface adverse events.
- Discussion of clinical management strategies.
Main Results:
- Identified ocular adverse reactions across multiple targeted drug classes including EGFR, HER2, FGFR, SERM, VEGFR, aromatase inhibitors, proteasome inhibitors, ADCs, BTK, FLT3, and CDK inhibitors.
- Detailed the spectrum of ocular surface toxicities associated with these agents.
- Underscored the clinical significance of these side effects.
Conclusions:
- Clinicians must actively monitor and manage ocular surface health in patients receiving targeted cancer therapies.
- Early detection and prompt intervention are essential for mitigating visual impairment.
- Balancing effective cancer treatment with optimal visual preservation is paramount.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:27Tumor Immunotherapy
01:28Angle Closure Glaucoma: Treatment
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...